FDA must be worried—they’ve extended the comment period for the supplement guidance. We must use the opportunity to flood the agency with more comments. Please help out! Highest-Level Action Alert!
This past August, the FDA issued its long delayed guidance detailing how the supplement industry can bring new products to the market. The guidance deals with how and whether the supplement industry is allowed to innovate and create new supplements, also called “new dietary ingredients” (NDIs for short).
There are many, many problems with this guidance that you can read more about in our original coverage, but the main point is simple: if this current guidance becomes final with no modifications, consumers will very likely lose access to thousands of supplements. In some cases, ingredients that have been available as supplements could be handed over to the pharmaceutical industry. Innovation will be quashed.
We believe this is exactly what the FDA and its Big Pharma allies want. Only the American public can stop it.
Over the last few months, ANH-USA members and other stakeholders have inundated the FDA with comments—addressing the substance of the guidance as well as asking the FDA to extend the comment period to give the public ample time to respond.
The FDA paid attention because the only thing it fears is Congress—and the only thing Congress fears is the voters. The agency responded and agreed to extend the comment period on the guidance sixty days, to December 12, 2016.
We cannot stress how critical it is for everyone who has not yet submitted a comment to the FDA on this issue to do so now. The guidance will threaten too many vital supplements and effectively kill innovation in the supplement industry. We must stop the FDA from moving forward with its new regulations disguised as a “guidance” document.
Highest-Level Action Alert! If you haven’t already, send a message to the FDA detailing all of the problems with their NDI guidance document. Please send your message immediately!
FDA To Redefine “Healthy” Once Again
Drug-Resistant “Super Gonorrhea” on the Rise
